

Collaborative Working Project executive summary

Project title	ABCD DKA collaborative working Project
Partner organisation/s	Association of British Clinical Diabetologists (ABCD) Sanofi
Project rationale	<p>Overarching aim:</p> <p>To standardise diabetes-related ketoacidosis (DKA) management processes by improving adherence to the Joint British Diabetes Societies-Inpatient (JBDS-IP) guidelines using quality improvement methodology and potentially reduce the total duration of DKA episode in a sustainable manner.</p> <ul style="list-style-type: none"> • To contribute towards the establishment of a centralised data base by having uniform data collection across multiple centres and consolidated analysis to limit time gap between data collection and intervention based on results. All data to be collated and analysed by a data analyst employed by ABCD. Sanofi will not be collecting or analysing the source data. • To provide regular feedback to relevant stakeholders and facilitate tailored interventions to abet sustained improvement in DKA care. • Aim to have at least 1 pilot site per region in first phase (10 regions on total)
Project period	March 2023 to March 2025
Project objectives	<p>Expected benefits for patients Improved high quality care for DKA in concordance with JBDS-IP guidelines, reducing DKA duration.</p> <p>Expected benefits for the Association of British Clinical Diabetologists (ABCD), patient and NHS:</p> <ul style="list-style-type: none"> • QI with a common data repository coupled with regular feedback facilitates consistent delivery of high-quality care with reduced discrepancies in management across sites for patients admitted with DKA.

	<ul style="list-style-type: none"> • Potential reduction in DKA duration, length of hospitalisation for patients and subsequent alleviation of the costs incurred in the treatment of DKA. • Better patient outcomes and more efficient patient pathway for patients admitted with DKA • Increased skill and knowledge for NHS staff managing DKA in hospital. • Increased capability to audit current levels of provision and make interventions to improve patient care • Sharing of best practice care across NHS organisations <p>Expected benefits for Sanofi</p> <ul style="list-style-type: none"> • Greater understanding of the needs of the healthcare professional in managing type 1 and type 2 diabetes patients who experience complications • Opportunity for Sanofi to use our collective skills and resources to reduce inconsistency of care and improve patient outcomes regionally and nationally. • Improved reputation with relevant NHS organisations across the project sites • As Sanofi produce medicines within this disease area if overall patient care is optimised there may be an increase in the usage of these products in line with National and local guidelines
<p>Contact details</p>	<p>Prof. Parth Narendran - Elected committee member ABCD (diabetes care LTD)</p> <p>483 Green lanes, London, N134BS</p> <p>Fleur Chandler – Head of Market Access</p> <p>Sanofi -410 Thames valley Park Drive, Reading, Berkshire, RG6 1PT</p> <p>GB-marketaccess@sanofi.com</p>